Guidelines for treatment of leishmaniasis in dogs

Journal of the American Veterinary Medical Association

Volumn 236, Issue 11, 2010, Pages 1192-1198

  Oliva, Gaetano ^a   Roura, Xavier ^b   Crotti, Alberto ^c   Maroli, Michele ^d   Castagnaro, Massimo ^e   Gradoni, Luigi ^d   Lubas, George ^f   Paltrinieri, Saverio ^g   Zatelli, Andrea ^h   Zini, E ⁱ  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Associated Veterinary Clinic   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f UNIVERSITY OF PISA   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h Veterinary Clinic Pirani   (Italy)

ⁱ UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPROTOZOAL AGENT;

ANIMAL; ANIMAL DISEASE; ARTICLE; CLASSIFICATION; DOG; DOG DISEASE; LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; DOG DISEASES; DOGS; LEISHMANIASIS;

CANIS FAMILIARIS;

EID: 77953490995     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.236.11.1192     Document Type: Article

References (73)

1. Amusategui I, Sainz A, Tesouro MA. Effects of antimonial therapy for canine leishmaniasis on antibody titer. Ann N Y Acad Sci 1998; 849: 444-446. (Pubitemid 28369580)
2. Amusategui I, Sainz A, Tesouro MA. Evolution of serum albumin/globulin ratio after antimonial therapy in canine leishmaniasis. Ann N Y Acad Sci 1998; 849: 447-449. (Pubitemid 28369581)
3. Paltrinieri S, Solano-Gallego L, Fondati A, et al. Guidelines for diagnosis and clinical classification of leishmaniasis in dogs. J Am Vet Med Assoc 2010; 236: 1184-1191.
4. Aste G, Di Tommaso M, Steiner JM, et al. Pancreatitis associated with N-methyl-glucamine therapy in a dog with leishmaniasis. Vet Res Commun 2005; 29(suppl 2): 269-272. (Pubitemid 41631410)
5. Barbosa Santos EG, Marzochi MC, Conceição NE et al. N-methylglucamine antimonate (SbV+): intralesional canine tegumentary leishmaniasis therapy. Parasite 1998; 5: 175-180.
6. Belloli C, Ceci L, Carli S, et al. Disposition of antimony and aminosidine in dogs after administration separately and together: implications for therapy of leishmaniasis. Res Vet Sci 1995; 58: 123-127.
7. Bourdoiseau G, Bonnefont C, Hoareau E, et al. Specific IgG1 and IgG2 antibody and lymphocyte subset levels in naturally Leishmania infantum-infected treated and untreated dogs. Vet Immunol lmmunopathol 1997; 59: 21-30. (Pubitemid 28044509)
8. Carrió J, Riera C, Gállego M, et al. In vitro activity of pentavalent antimony derivatives on promastigotes and intracellular amastigotes of Leishmania infantum strains from humans and dogs in Spain. Acta Trop 2001; 79: 179-183. (Pubitemid 32441789)
9. Chapman WL. Jr, Hanson WL, Alving CR, et al. Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog. Am J Vet Res 1984; 45: 1028-1030.
10. Gradoni L, Maroli M, Gramiccia M, et al. Leishmania infantum infection rates in Phlebotomus perniciosus fed on naturally infected dogs under antimonial treatment. Med Vet Entomol 1987; 1: 339-342.
11. Gramiccia M, Gradoni L, Orsini S. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment. Ann Trop Med Parasitol 1992; 86: 613-620. (Pubitemid 23090621)
12. Guarga JL, Moreno J, Lucientes J, et al. Evaluation of a specific immunochemotherapy for the treatment of canine visceral leishmaniasis. Vet Immunol lmmunopathol 2002; 88: 13-20. (Pubitemid 34667159)
13. lkeda-Garcia FA, Lopes RS, Ciarlini PC, et al. Evaluation of renal and hepatic functions in dogs naturally infected by visceral leishmaniasis submitted to treatment with meglumine antimoniate. Res Vet Sci 2007; 83: 105-108.
14. Ikeda-Garcia FA, Lopes RS, Marques FJ, et al. Clinical and parasitological evaluation of dogs naturally infected by Leishmania (Leishmania) chagasi submitted to treatment with meglumine antimoniate. Vet Parasitol 2007; 143: 254-259. (Pubitemid 46116806)
15. Mancianti F, Gramiccia M, Gradoni L, et al. Studies on canine leishmaniasis control. 1. Evolution of infection of different clinical forms of canine leishmaniasis following antimonial treatment. Trans R Soc Trop Med Hyg 1988; 82: 566-567.
16. Moritz A, Steuber S, Greiner M. Clinical follow-up examination after treatment of canine leishmaniasis. Tokai J Exp Clin Med 1998; 23: 279-283. (Pubitemid 29403774)
17. Oliva G, Gradoni L, Cortese L, et al. Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniasis. Ann Trop Med Parasitol 1998; 92: 165-171. (Pubitemid 28140465)
18. Riera C, Valladares JE, Gallego M, et al. Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate. Vet Parasitol 1999; 84: 33-47. (Pubitemid 29298175)
19. Schettini DA, Costa Val AP, Souza LF, et al. Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate. Braz J Med Biol Res 2005; 38: 1879-1883.
20. Slappendel RJ, Teske E. The effect of intravenous or subcutaneous administration of meglumine antimonate (Glucantime) in dogs with leishmaniasis. A randomized clinical trial. Vet Q 1997; 19: 10-13.
21. Steuber S, Moritz A, Schirrmann I, et al. PCR follow-up examination after treatment of canine leishmaniosis (CanL). Tokai J Exp Clin Med 1998; 23: 285-292. (Pubitemid 29403775)
22. Tassi P, Ormas P, Madonna M, et al. Pharmacokinetics of Nmethylglucamine antimoniate after intravenous, intramuscular and subcutaneous administration in the dog. Res Vet Sci 1994; 56: 144-150.
23. Valladares JE, Alberola J, Esteban M, et al. Disposition of antimony after the administration of N-methylglucamine antimoniate to dogs. Vet Rec 1996; 138: 181-183.
24. Valladares JE, Riera C, González-Ensenyat P, et al. Long term improvement in the treatment of canine leishmaniosis using an antimony liposomal formulation. Vet Parasitol 2001; 97: 15-21.
25. Vouldoukis I, Drapier JC, Nūssler AK, et al. Canine visceral leishmaniasis: successful chemotherapy induces macrophage antileishmanial activity via the L-arginine nitric oxide pathway. Antimicrob Agents Chemother 1996; 40: 253-256.
26. Vouldoukis I, Rougier S, Dugas B, et al. Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate. Vet Parasitol 2006; 135: 137-146.
27. Cortese L, Pelagalli A, Piantedosi D, et al. The effects of prednisone on haemostasis in leishmaniotic dogs treated with meglumine antimoniate and allopurinol. Vet J 2008; 177: 405-410.
28. Denerolle P, Bourdoiseau G. Combination allopurinol and antimony treatment versus antimony alone and allopurinol alone in the treatment of canine leishmaniasis (96 cases). J Vet Intern Med 1999; 13: 413-415.
29. Fernández-Pérez FJ, Gómez-Muñoz MT, Méndez S, et al. Leishmania-specific lymphoproliferative responses and IgG1/IgG2 immunodetection patterns by Western blot in asymptomatic, symptomatic and treated dogs. Acta Trop 2003; 86: 83-91.
30. Ferrer L, Aisa MJ, Roura X, et al. Serological diagnosis and treatment of canine leishmaniasis. Vet Rec 1995; 136: 514-516.
31. Manna L, Reale S, Vitale F, et al. Real-time PCR assay in Leishmania-infected dogs treated with meglumine antimoniate and allopurinol. Vet J 2008; 177: 279-282.
32. Martínez-Subiela S, Bernal LJ, Cerón JJ. Serum concentrations of acute-phase proteins in dogs with leishmaniosis during shortterm treatment. Am J Vet Res 2003; 64: 1021-1026.
33. Miranda S, Martorell S, Costa M, et al. Characterization of circulating lymphocyte subpopulations in canine leishmaniasis throughout treatment with antimonials and allopurinol. Vet Parasitol 2007; 144: 251-260.
34. Rodríguez A, Solano-Gallego L, Ojeda A, et al. Dynamics of Leishmania-specific immunoglobulin isotypes in dogs with clinical leishmaniasis before and after treatment. J Vet Intern Med 2006; 20: 495-498.
35. Solano-Gallego L, Riera C, Roura X, et al. Leishmania infantumspecific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. Evolution in the course of infection and after treatment. Vet Parasitol 2001; 96: 265-276.
36. Cavaliero T, Arnold P, Mathis A, et al. Clinical, serologic, and parasitologic follow-up after long-term allopurinol therapy of dogs naturally infected with Leishmania infantum. J Vet Intern Med 1999; 13: 330-334.
37. Gothe R, Nolte I, Kraft W. Leishmaniasis in dogs in Germany: epidemiological case analysis and alternatives to conventional causal therapy. Tierarztl Prax 1997; 25: 68-73.
38. Liste F, Gascon M. Allopurinol in the treatment of canine visceral leishmaniasis. Vet Rec 1995; 137: 23-24.
39. Pasa S, Toz SO, Voyvoda H, et al. Clinical and serological followup in dogs with visceral leishmaniosis treated with allopurinol and sodium stibogluconate. Vet Parasitol 2005; 128: 243-249. (Pubitemid 40312433)
40. Pennisi MG, Reale S, Giudice SL, et al. Real-time PCR in dogs treated for leishmaniasis with allopurinol. Vet Res Commun 2005; 29(suppl 2): 301-303. (Pubitemid 41631418)
41. Plevraki K, Koutinas AF, Kaldrymidou H, et al. Effects of allopurinol treatment on the progression of chronic nephritis in Canine leishmaniosis (Leishmania infantum). J Vet Intern Med 2006; 20: 228-233.
42. Sasanelli M, Paradies P, de Caprariis D, et al. Acute-phase proteins in dogs naturally infected with Leishmania infantum during and after long-term therapy with allopurinol. Vet Res Commun 2007; 31(suppl 1): 335-338. (Pubitemid 47244337)
43. Vercammen F, DeDeken R. Antibody kinetics during allopurinol treatment in canine leishmaniasis. Vet Rec 1996; 139: 264. (Pubitemid 26326405)
44. Vercammen F, De Deken R. Treatment of canine visceral leishmaniasis with allopurinol. Vet Rec 1995; 137: 252.
45. Vercammen F, Fernandez-Perez FJ, del Amo C, et al. Follow-up of Leishmania infantum naturally infected dogs treated with allopurinol: immunofluorescence antibody test, ELISA and Western blot. Acta Trop 2002; 84: 175-181. (Pubitemid 35346560)
46. Poli A, Sozzi S, Guidi G, et al. Comparison of aminosidine (paromomycin) and sodium stibogluconate for treatment of canine leishmaniasis. Vet Parasitol 1997; 71: 263-271. (Pubitemid 27400312)
47. Vexenat JA, Olliaro PL, Fonseca de Castro JA, et al. Clinical recovery and limited cure in canine visceral leishmaniasis treated with aminosidine (paromomycin). Am J Trop Med Hyg 1998; 58: 448-453.
48. Cortadellas O. Initial and long-term efficacy of a lipid emulsion of amphotericin B desoxycholate in the management of canine leishmaniasis. J Vet Intern Med 2003; 17: 808-812.
49. Lamothe J. Activity of amphotericin B in lipid emulsion in the initial treatment of canine leishmaniasis. J Small Anim Pract 2001; 42: 170-175.
50. Oliva G, Gradoni L, Ciaramella P, et al. Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum. J Antimicrob Chemother 1995; 36: 1013-1019.
51. Manna L, Vitale F, Reale S, et al. Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis. Vet J 2009; 182: 441-445.
52. Mirò G, Oliva G, Cruz I, et al. Multi-centre and controller clinical field study to evaluate the efficacy and safety of the combination of miltefosine and allopurinol in the treatment of canine leishmaniosis. Vet Dermatol 2008; 19(suppl 1): 7-8.
53. Mateo M, Maynard L, Vischer C, et al. Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis. Parasitol Res 2009; 105: 155-162.
54. Rhalem A, Sahibi H, Lasri S, et al. Analysis of immune responses in dogs with canine visceral leishmaniasis before, and after, drug treatment. Vet Immunol Immunopathol 1999; 71: 69-76.
55. Pennisi MG, De Majo M, Masucci M, et al. Efficacy of the treatment of dogs with leishmaniosis with a combination of metronidazole and spiramycin. Vet Rec 2005; 156: 346-349.
56. Rougier S, Vouldoukis I, Fournell S, et al. Efficacy of different treatment regimens of marbofloxacin in canine visceral leishmaniosis: a pilot study. Vet Parasitol 2008; 153: 244-254.
57. Bianciardi P, Fasanella A, Foglia Manzillo V, et al. The efficacy of enrofloxacin, alone or combined with metronidazole, in the therapy of canine leishmaniasis. Parasitol Res 2004; 93: 486-492.
58. Gómez-Ochoa P, Castillo JA, Gascón M, et al. Use of domperidone in the treatment of canine visceral leishmaniasis: a clinical trial. Vet J 2009; 179: 259-263.
59. Gradoni L, Bryceson A, Desjeux P Treatment of Mediterranean visceral leishmaniasis. Bull World Health Organ 1995; 73: 191-197.
60. Gradoni L, Gramiccia M, Scalone A. Visceral leishmaniasis treatment, Italy. Emerg Infect Dis 2003; 9: 1617-1620.
61. Shapiro TA, Were JB, Danso K, et al. Pharmacokinetics and metabolism of allopurinol riboside. Clin Pharmacol Ther 1991; 49: 506-514.
62. Di Martino L, Mantovani MP, Gradoni L, et al. Low dosage combination of meglumine antimoniate plus allopurinol as first choice treatment of infantile visceral leishmaniasis in Italy. Trans R Soc Trop Med Hyg 1990; 84: 534-535.
63. Sundar S, Rai M. Advances in the treatment of leishmaniasis. Curr Opin Infect Dis 2002; 15: 593-598.
64. Davidson RN, den Boer M, Ritmeijer K. Paromomycin. Trans R Soc Trop Med Hyg 2009; 103: 653-660.
65. Davidson RN. Practical guide for the treatment of leishmaniasis. Drugs 1998; 56: 1009-1018.
66. Sindermann H, Engel J. Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg 2006; 100(suppl 1): S17-S20.
67. Croft SL, Neal RA, Pendergast W, et al. The activity of alkylphosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol 1987; 36: 2633-2666.
68. Kuhlencord A, Maniera T, Eibl H, et al. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 1992; 36: 1630-1634.
69. Jha TK, Sundar S, Thakur CP, et al. Miltefosine, an oral agent, for the treatment of Indian Visceral Leishmaniasis. N Engl J Med 1999; 341: 1795-1800.
70. Sundar S, Chatteryee M. Visceral leishmaniasis-current therapeutic modalities. Indian J Med Res 2006; 123: 345-352.
71. Jha SN, Singh NKP, Jha TK. Changing response to diamidine compound in cases of kala-azar unresponsive to antimonials. J Assoc Physicians India 1991; 39: 314-316.
72. Berczi I, Bertok L, Chow DA. Natural immunity and neuroimmune host defense. Ann N Y Acad Sci 2000; 917: 248-257.
73. Hinterberger-Fischer M. Prolactin as pro-inflammatory cytokine. Consideration on consolidated immunotherapy after high dosage therapy. Acta Med Austriaca Suppl 2000; 52: 16-20.